STX 001
Alternative Names: STX-001Latest Information Update: 06 Jun 2025
At a glance
- Originator Massachusetts Institute of Technology
- Developer Strand Therapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; RNA
- Mechanism of Action Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 26 May 2025 Efficacy and adverse events data from a phase I/II trial in Solid tumours released by Strand Therapeutics
- 03 May 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia (Injection) (NCT06249048)
- 03 May 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Australia (Injection) (NCT06249048)